MEDIF (MEDIF) Stock Price & Analysis
MEDIF (MEDIF) rose 0.00% to USD 0.06 as of July 25, 2026 at 15:00 UTC, according to Nexqual real-time market data.
MEDIF last closed at USD 0.06; the session ranged USD 0.05–0.06 on volume of 25,000 shares. Market capitalization is $24.22M, with a 52-week range of USD 0.04–0.08 (OQB). Source: Nexqual, July 25, 2026 at 15:00 UTC.
Key Statistics (as of July 25, 2026 at 15:00 UTC)
| Price | USD 0.06 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0.06 |
| Open | USD 0.05 |
| Day Range | USD 0.05 – 0.06 |
| 52-Week Range | USD 0.04 – 0.08 |
| Volume | 25,000 shares |
| Market Cap | $24.22M |
| Exchange | OQB |
Technical Analysis (MEDIF)
Nexqual's technical model rates MEDIF "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of July 25, 2026 at 15:00 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 53.44 (neutral) |
| vs SMA50 | Above (USD 0.06) |
| MACD | 0 (positive) |
Analyst Ratings (MEDIF)
Wall Street analysts rate MEDIF "None", per Nexqual as of July 25, 2026 at 15:00 UTC.
| Consensus Rating | None |
|---|
Earnings (MEDIF)
| Next Earnings Date | 2026-08-13 |
|---|
Source: Nexqual, July 25, 2026 at 15:00 UTC.
Financials & Fundamentals (MEDIF)
| Total Revenue | $43.28M |
|---|---|
| Revenue Growth (YoY) | -17.10% |
| Gross Margin | +28.96% |
| Operating Margin | -11.09% |
| Profit Margin | -20.21% |
| ROE | -22.33% |
| Debt / Equity | 0.05 |
| Current Ratio | 3.02 |
| Total Cash | $10.35M |
| Total Debt | $18,000 |
| Free Cash Flow | $5.31M |
Source: Nexqual, July 25, 2026 at 15:00 UTC.
Financial Health Score (MEDIF)
Nexqual rates MEDIF's overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 15:00 UTC.
| Growth | Solid — Revenue +8% YoY (annual) |
|---|---|
| Profitability | Weak — Not yet profitable — scaling phase |
| Balance Sheet | Strong — $10M cash, no debt |
| Cash Flow | Solid — FCF $5M, 12% margin |
| Efficiency | Critical — ROE -22%, ROA -10.2% |
Ownership (MEDIF)
| Insider Ownership | +11.64% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 424.86M |
| Float | 385.17M |
Source: Nexqual, July 25, 2026 at 15:00 UTC.
Leadership (MEDIF)
MEDIF is led by Greg Hunter, CFO & Interim CEO, per Nexqual as of July 25, 2026 at 15:00 UTC.
| CFO & Interim CEO | Greg Hunter |
|---|---|
| Executive Vice President of Global Accounts | Kirk Binns |
Major Backers & Investors (MEDIF)
Notable institutional backers of MEDIF include Amplify ETF Trust-Amplify Seymour Cannabis ETF, according to Nexqual as of July 25, 2026 at 15:00 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Amplify ETF Trust-Amplify Seymour Cannabis ETF | 0.71% |
Source: Nexqual, July 25, 2026 at 15:00 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| KHRNF | KHIRON LIFE SCIENCES CORP | USD 0 | ▲ 0% |
| FLWPF | THE FLOWR CORPORATION | USD 0 | ▲ 0% |
| ELLXF | Elixinol Wellness Ltd. | USD 0.01 | ▼ 2.67% |
| ITHUF | iAnthus Capital Holdings, Inc. | USD 0 | ▲ 0% |
| CWBHF | Charlotte's Web Holdings Inc. | USD 0.24 | ▲ 8.11% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 15:00 UTC. This page is informational and not investment advice.